MGTX · MeiraGTx Holdings plc

MeiraGTx Holdings plc has entered into a material definitive agreement in the form of an Underwriting Agreement with BofA Securities, Inc. and Goldman Sachs & Co. LLC to facilitate a public offering of its ordinary shares. The company is issuing 11,111,111 shares at a price of $9.00 per share. This capital raise is significant as it provides the company with approximately $93.3 million in net proceeds, which will bolster its balance sheet for the foreseeable future. The company explicitly stated that these proceeds, combined with existing cash reserves, are expected to fund operating expenses and capital expenditure requirements into the second half of 2028. This extended runway is critical for a clinical-stage gene therapy company, specifically supporting the potential commercial launches of key product candidates: bota-vec for X-linked retinitis pigmentosa and AAV-hAQP1 for radiation-induced xerostomia. The transaction was conducted pursuant to an effective shelf registration statement on Form S-3, indicating a streamlined execution process. The closing is subject to customary conditions and is expected to finalize on April 17, 2026.